English | 简体中文 | 繁體中文 | 한국어
Share:
Sands Capital reports 5.7% holding in Galapagos

Mechelen, Belgium; 8 January 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital Management, LLC.

Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 27 December 2018 from Sands Capital Management, LLC, who notified that it held 3,092,264 of Galapagos' voting securities (consisting of American Depository Shares) on 13 September 2018. On this date, Sands Capital Management, LLC, crossed the 5% threshold of Galapagos' voting securities by acquiring additional securities. These 3,092,264 securities represented 6.02% of Galapagos' then outstanding 51,337,763 shares. Since the number of outstanding Galapagos shares currently stands at 54,465,421, the 3,092,264 securities of Sands Capital Management currently represent 5.7%. The full transparency notice is available on the Galapagos website.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contact

Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784

Sofie Van Gijsel
Director IR
+32 485 19 14 15
[email protected]

Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
[email protected]



[1]     Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.





This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)  
July 29, 2019 07:00 ET
Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness  
July 26, 2019 14:06 ET
Eastman Announces Second-Quarter 2019 Financial Results  
July 26, 2019 05:29 ET
Eastman Announces Second-Quarter 2019 Financial Results  
July 25, 2019 23:05 ET
Strong clinical progress in H1 and transformative collaboration with Gilead announced  
July 25, 2019 22:02 ET
Verisk to Acquire PASCO's Aerial Survey Business in U.S. to Strengthen Data Acquisition Capacity under Geomni  
July 25, 2019 05:29 ET
Verisk to Acquire PASCO's Aerial Survey Business in U.S. to Strengthen Data Acquisition Capacity under Geomni  
July 24, 2019 23:01 ET
Eastman Schedules Second-Quarter 2019 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast  
July 8, 2019 22:59 ET
AIR Publishes Its Catastrophe Exposure Data Schema Publicly  
July 1, 2019 16:59 ET
AIR Worldwide Releases Expanded Inland Flood Model for Central Europe  
June 25, 2019 16:29 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: